Molecular Mechanisms Involved in Schwann Cell Plasticity by Angélique Boerboom et al.
REVIEW
published: 17 February 2017
doi: 10.3389/fnmol.2017.00038
Frontiers in Molecular Neuroscience | www.frontiersin.org 1 February 2017 | Volume 10 | Article 38
Edited by:
Margaret Su-chun Ho,
Tongji University, China
Reviewed by:
Xavier Navarro,
Autonomous University of Barcelona,
Spain
Melissa R. Andrews,
University of St Andrews, UK
Georg Zoidl,
York University, Canada
Helmar Lehmann,
University Hospital Cologne, Germany
*Correspondence:
Rachelle Franzen
rfranzen@ulg.ac.be
Received: 22 December 2016
Accepted: 31 January 2017
Published: 17 February 2017
Citation:
Boerboom A, Dion V, Chariot A and
Franzen R (2017) Molecular
Mechanisms Involved in Schwann Cell
Plasticity. Front. Mol. Neurosci. 10:38.
doi: 10.3389/fnmol.2017.00038
Molecular Mechanisms Involved in
Schwann Cell Plasticity
Angélique Boerboom 1, Valérie Dion 1, Alain Chariot 2, 3 and Rachelle Franzen 1*
1GIGA-Neurosciences, University of Liège, Liège, Belgium, 2GIGA-Molecular Biology of Diseases, University of Liège, Liège,
Belgium, 3Walloon Excellence in Lifesciences and Biotechnology (WELBIO), Wavre, Belgium
Schwann cell incredible plasticity is a hallmark of the utmost importance following
nerve damage or in demyelinating neuropathies. After injury, Schwann cells undergo
dedifferentiation before redifferentiating to promote nerve regeneration and complete
functional recovery. This review updates and discusses the molecular mechanisms
involved in the negative regulation of myelination as well as in the reprogramming of
Schwann cells taking place early following nerve lesion to support repair. Significant
advance has been made on signaling pathways and molecular components that regulate
SC regenerative properties. These include for instance transcriptional regulators such
as c-Jun or Notch, the MAPK and the Nrg1/ErbB2/3 pathways. This comprehensive
overview ends with some therapeutical applications targeting factors that control
Schwann cell plasticity and highlights the need to carefully modulate and balance this
capacity to drive nerve repair.
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INTRODUCTION
The peripheral nervous system (PNS) shows a surprising capacity of regeneration compared to the
central nervous system (CNS). This ability of peripheral nerves to recover quickly following damage
is to a large extent due to the remarkable plasticity of Schwann cells (SCs), the glial cells of the PNS
(Jessen et al., 2015). SCs are derived from neural crest cells that differentiate into SC precursors
Abbreviations: ALS, Amyotrophic lateral sclerosis; BACE1, Beta-Site amyloid precursor protein cleaving enzyme 1; BDNF,
Brain-derived neurotrophic factor; BMP7, Bone morphogenetic protein 7; Cadm3, Cell adhesion molecule 3; cAMP, Cyclic
adenosine monophosphate; Cdkn1c, Cyclin-dependent kinase inhibitor 1C; CIDP, Chronic inflammatory demyelinating
polyneuropathy; CMT, Charcot-Marie-Tooth; Cthrc1, Collagen triple helix repeat containing 1; EZH2, Enhancer of zeste
homolog 2; Dixdc1, DIX domain containing-1; DDIT4, DNA damage-inducible transcript 4 protein; Dlg1, Disks large
homolog 1; Dock7, Dedicator of cytokinesis protein 7; DRG, Dorsal root ganglion; Dusp15, Dual specificity phosphatase
15; Egr-1, Early growth response protein 1; Egr-2/Krox-20Early growth response 2; Egr-3, Early growth response protein 3;
Erk, Extracellular signal regulated kinase; GDNF, Glial cell-derived neurotrophic factor; GFAP, Glial fibrillary acidic protein;
GPCR, G protein-coupled receptor; Id2, DNA-binding protein inhibitor 2; IVIG, Immunoglobulins; JNK, c-jun N-terminal
kinase; LKB1/STK11, Liver kinase B1/ Serine/threonine-protein kinase 11; LPA1, Lysophosphatidic acid receptor 1; LXR,
Liver X receptor; MAPK, Mitogen activated protein kinase; MBP, Myelin basic protein; MPZ, Myelin protein zero; MyD88,
Myeloid differentiation primary response gene 88; NF-κB, Nuclear factor-kappa B; NMJ, Neuromuscular junction; Notch,
Neurogenic locus notch homolog protein; Nrg1, Neuregulin 1; NuRD, Nucleosome remodeling and deacetylase complex;
p75NTR, Low affinity neurotrophin receptor; Pax-3, Paired box protein 3; PI 3-kinase, Phosphatidylinositol 3-kinase;
PMP22, Peripheral myelin protein 22; Pou3f1/Oct6, POU domain class 3 transcription factor / Octamer-binding factor 6;
PTEN, Phosphatase and tensin homolog deleted on chromosome 10; S1PR, Sphingosine-1-phosphate receptor; Sam68, Src-
associated in mitosis of 68 kD; Sox2, SRY-related HMG-box gene 2; SSeCKS, Src-suppressed protein kinace C substrate;
STK11, Serine/threonine protein kinase; TACE, Tumor necrosis factor-α–converting enzyme; TGFβ, Transforming growth
factor beta; Zeb2, Zinc-finger E-box-binding homeobox 2.
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and then into immature SCs between E12 and E15 in mice.
Around birth, axonal sorting and myelination start in the
peripheral nerves. Some SCs establish a 1:1 relationship with
large-diameter axons, wrap them multiple times to form a thick
and compact myelin sheath. Myelin-forming SCs allow the fast
conduction of action potentials by insulating the axons. The non-
myelinating SCs typically associate with several small-diameter
axons to form Remak bundles. Nerve homeostasis, trophic
support and myelin maintenance are other important functions
of SCs in adulthood (Jessen and Mirsky, 2005).
Besides their major roles in normal nerve physiology, SCs
play a key function for repair in many pathological conditions
thanks to their striking plasticity (Zochodne, 2008). For example,
after a peripheral nerve injury, they are capable of switching into
a SC immature-like phenotype that drives nerve repair. Over
the last decades, major progress has been made in unraveling
molecular mechanisms and signaling pathways that drive SC
dedifferentiation and regulate their plasticity. In this review,
we will update and discuss the recent studies that identified
molecular components involved in SC plasticity and their
possible therapeutic implications.
REMARKABLE PLASTICITY AND
REGENERATIVE PROPERTIES OF
SCHWANN CELLS AFTER PERIPHERAL
NERVE INJURY
The unique plasticity of SCs has been extensively studied in
transgenic animals after cut or crush injuries. Indeed, following
a nerve lesion, quiescent, highly specialized myelinating and
non-myelinating SCs reprogram into proliferative progenitor-
like repair SCs that drive the entire regeneration process (Chen
et al., 2007; Jessen and Mirsky, 2016). The reprogramming of
SCs in physiopathological conditions is most of the time defined
as dedifferentiation. However, transdifferentiation seems more
appropriate, as repair SCs, besides re-expressing immature SC
markers, exhibit completely different features (Arthur-Farraj
et al., 2012). Indeed, the injury-induced conversion of mature
SCs in regeneration-promoting cells is an active phenomenon. It
involves a down-regulation of pro-myelinating genes including
early growth response 2 (Egr-2, more frequently named Krox-
20), POU domain class 3 transcription factor 1 (Pou3f1 or
Oct-6), myelin protein zero (MPZ) or myelin basic protein
(MBP) as well as an up-regulation of markers of immature,
de-differentiated SCs such as c-Jun, low affinity neurotrophin
receptor (p75NTR) or glial fibrillary acidic protein (GFAP) but
also specific repair-supportive genes (Jessen and Mirsky, 2008).
Following damage, the nerve undergoes a series of complex
multicellular and molecular events in which SCs play a role of
orchestrator (Figure 1).
Quickly after nerve injury, damaged axons in the distal stump
degenerate in an active process called Wallerian degeneration
(Waller, 1850). Yet unidentified signals from damaged nerves
induce the reprogramming of SCs. These downregulate pro-
myelinating genes and start clearing their myelin sheaths
through a mechanism of autophagy called myelinophagy
(Gomez-Sanchez et al., 2015). Axonal and myelin debris are
also phagocyted by resident and blood-derived macrophages
recruited by SCs (Hirata and Kawabuchi, 2002; Lee et al., 2006;
Barrette et al., 2008). An inflammatory reaction occurs: many
blood cells invade the lesion site and secrete numerous cytokines
and chemokines (Martini et al., 2008; Gaudet et al., 2011;
Rotshenker, 2011). Following nerve axotomy, particularly, the
basal lamina of SCs and the connective tissue are interrupted
(Zochodne, 2008). A tissue bridge is formed between the two
stumps of the nerve over the lesion site. Fibroblasts play a major
role in building this bridge by interacting with SCs (Parrinello
et al., 2010). Newly formed vasculature is also crucial to guide the
SCs and the growing axons through the lesion site (Cattin et al.,
2015). Many chemical and physical interactions happen between
the actors present in the injured nerve, creating a permissive and
favorable environment for regeneration (Cattin and Lloyd, 2016).
Irrespective of whether the injury is a crush or a cut, repair
SCs in the distal stump proliferate, secrete several trophic factors
that support glial and neuronal survival and regrowth including
artemin, brain-derived neurotrophic factor (BDNF) or glial cell
line-derived neurotrophic factor (GDNF) (Fernandez-Valle et al.,
1995; Kim et al., 2000; Boyd and Gordon, 2003; Fontana et al.,
2012). They also align in tracts named bands of Büngner and
provide a trophic and physical support for axons to regrow
and reinnervate correctly their targets (Weinberg and Spencer,
1978; Stoll and Müller, 1999). At the neuromuscular junction,
specialized terminal SCs direct reinnervation by helping the
axons to find their paths toward their appropriate sites (Son
and Thompson, 1995). After axonal regeneration, repair SCs
readily exit the cell cycle and differentiate again into myelinating
and non-myelinating SCs to support the complete functional
recovery. Nevertheless, most of the time, the newly-formed
myelin sheaths are shorter and thinner than expected based on
axonal diameter (Schröder, 1972).
MOLECULAR MECHANISMS THAT
MODULATE SCHWANN CELL PLASTICITY
The adaptive reprogramming of SCs after a nerve injury is
a prerequisite for regeneration. Therefore, understanding the
molecular components that regulate the phenotypic change of
adult specialized SCs into repair-supportive SCs can lead to the
development of new therapeutics that can boost repair in various
peripheral neuropathies. In this section, we will review the most
relevant molecular components or pathways that have been
identified for controlling SC plasticity, the negative regulation
of myelination and their response to nerve injury (Tables 1, 2;
Figure 2).
Transcriptional Regulators
The Transcription Factor c-Jun
The transcription factor c-Jun does not appear to be essential
during SC development but multiple arguments demonstrate its
central function in SC reprogramming. Firstly, the time course
of c-Jun expression supports its role in SC plasticity. Indeed,
c-Jun is down-regulated post-natally during SC differentiation
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FIGURE 1 | Diagram of Schwann cell response to nerve injury. (1) Schematic representation of a single neuron with myelinating SCs and resident macrophages.
For simplification, the basal lamina around SCs is not shown. (2) After injury, the nerve distal to the injury site degenerates and undergoes a series of complex
multicellular and molecular events in which SCs play a role of orchestrator. SCs transdifferentiate into repair-promoting cells, creating a permissive and favorable
environment for nerve regeneration. SCs downregulate pro-myelinating genes and clear their myelin sheaths. They proliferate, secrete several pro-inflammatory
cytokines and trophic factors that support glial and neuronal survival and regrowth. Axonal and myelin debris are also phagocyted by resident and blood-derived
macrophages recruited by SCs. SCs interact with fibroblasts to build a bridge between the two stumps of the nerve over the lesion site. (3) Newly formed vasculature
guides the SCs and the growing axons through the lesion site. In the distal stump, SCs align in tracts named bands of Büngner to provide a trophic and physical
support for axons to regrow. (4) After axonal regeneration, transdifferentiated SCs readily exit the cell cycle, differentiate again and remyelinate the axons to support
the complete functional recovery. However, the newly-formed myelin sheaths are most of the time shorter and thinner than expected based on axonal diameter.
Specialized terminal SCs direct reinnervation by helping the axons to find their paths toward their initial targets. (5) Diagram displaying the various roles played by a
transdifferentiated SC to create a favorable environment for nerve repair.
and myelination and is highly up-regulated under pathological
conditions such as peripheral nerve injuries, demyelinating
diseases or other peripheral neuropathies (Stewart, 1995;
Parkinson et al., 2008; Hutton et al., 2011; Hantke et al., 2014;
Klein et al., 2014). Secondly, c-Jun is a negative regulator of
myelination and a cross-antagonist of Krox-20, one of the
main pro-myelinating transcription factors. Deletion of c-Jun in
SCs in vitro strikingly facilitates Krox-20-induced expression of
MBP or MPZ. Conversely, forced expression of c-Jun inhibits
the expression of myelin proteins. Moreover, the expression
of c-Jun and Krox-20 is mutually exclusive: while immature
SCs express relatively high levels of c-Jun and low levels of
Krox-20, myelinating cells switch to high levels of Krox-20
and low levels of c-Jun (Parkinson et al., 2004, 2008). Thirdly,
strong evidence in vivo exhibits the involvement of c-Jun
in major aspects of the SC response following nerve injury.
Myelination during development occurs normally in the c-Jun
conditional knockout mice (Parkinson et al., 2008). However,
the absence of c-Jun following a nerve lesion results in a
failure of generating the repair SCs, leading to impaired axonal
regeneration, target reinnervation and functional recovery. The
myelin sheath degradation and clearance are also strikingly
slowed in the absence of c-Jun in vitro and in vivo. Moreover,
mutant SCs fail to form the Büngner regenerative tracks and to
express the adhesion molecules and trophic factors critical for
nerve repair (Parkinson et al., 2008; Arthur-Farraj et al., 2012;
Fontana et al., 2012).
The role of c-Jun in SCs after nerve injury is to activate
a repair program to support regeneration. The high levels of
c-Jun found in different peripheral neuropathies that do not
involve nerve injuries like Charcot-Marie Tooth (CMT) raises
the question on the precise function of c-Jun in these diseases.
Does c-Jun counteract the pathology, attenuate its symptoms and
promote repair or does its up-regulation cause the disease? In
two models of demyelinating diseases, CMT1A and CMT1X, c-
Jun is increased in SCs that retain myelin differentiation (Hantke
et al., 2014; Klein et al., 2014). The myelin sheaths are also
relatively normal in a mouse mutant showing a 5–8 fold c-Jun
overexpression in SCs (levels that are lower than those seen
after a nerve cut though) (Jessen and Mirsky, 2016). Moreover,
c-Jun and repair-associated genes are up-regulated in a mouse
model in which the serine/threonine-protein kinase (LKB1, also
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TABLE 1 | Most relevant molecular components involved in Schwann cell plasticity, negative regulation of myelination and nerve repair.
Molecular
component
In vivo model(s) Phenotype(s) Reference(s)
TRANSCRIPTIONAL REGULATORS
c-Jun • MPZCre/cJunfl/fl • Injury: lack of trophic factor expression, no
alignment in bands of Büngner, no axon
regeneration and no functional recovery
Parkinson et al., 2008; Arthur-Farraj et al.,
2012; Fontana et al., 2012
Notch • MPZCre/RBPJfl/fl;Notchfl/fl ; NCIDCASL−STOPfl/fl
• Rats treated with Jagged1 (Notch signaling activator)
• Development: acceleration of myelination and
thicker myelin. Injury: delayed myelin breakdown
• Injury: improved axonal regeneration and
functional recovery
Woodhoo et al., 2009; Wang et al., 2015
Zeb2 • PLPCreERT2/Zeb2fl/fl • Injury: disturbed regeneration and lack of
remyelination
Quintes et al., 2016; Wu L. M. N. et al.,
2016
NF-κB • GFAP-IκBα-dn • Injury: delayed axonal regeneration and disturbed
remyelination
Morton et al., 2012
MAPK
Raf/Erk • MPZRafTR (tamoxifen-inducible Raf activation) • Normal adult nerve: transient activation leads to
demyelination, SC proliferation and increased
P75NTR expression. Sustained activation leads
to inflammation.
Napoli et al., 2012
Rac/JNK • Mice transfected with dominant negative
Rac1/Rac1-RNAi
• Mice injected with Rac inhibitor
• Dock7 shRNA transgenic mice (decrease of Rac/JNK
signaling)
• Injury: reduced myelin sheath fragmentation
• Injury: decreased c-Jun and p75NTR expression
• Development: enhanced myelin thickness
Jung et al., 2011; Yamauchi et al., 2011;
Shin et al., 2013
p38 • Mice injected with p38 inhibitor
• MPZCre/p38afl/fl
• New-born rats treated with BMP7 (activation of
p38MAPK signaling)
• Injury: reduced SC demyelination and
dedifferentiation
• Development: acceleration of myelination
Injury: delay in myelin clearance, small increase of
re-myelination
• Development: delayed peripheral myelination
Yang et al., 2012; Liu et al., 2016b;
Roberts et al., 2016
PI3K/Akt/mTOR
PTEN • PLPCreERT2/PTENfl/fl (hyper-activation of PI3K/Akt
signaling)
• PLPCreERT2/PTENfl/fltreated with rapamycin (mTOR
inhibitor)
• Development: hypermyelination, myelin
outfoldings
• Amelioration of the myelin pathology
Goebbels et al., 2010, 2012
Dlg1 • Mice injected with Dlg1 shRNA (activation of PI3K/Akt
signaling)
• MPZCreDlg1fl/f (activation of PI3K/Akt signaling)
• Development: myelin outfoldings and peripheral
nerve overmyelination
• Development: transient hypermyelination
Cotter et al., 2010; Noseda et al., 2013
DDIT4 • DDIT4 KO mouse (over-activation of PI3K/AKT/mTOR
signaling)
• Development: sustained hypermyelination Noseda et al., 2013
WNT SIGNALING AND LXR
LXR • LXR KO mouse
• Mice treated with paraquat (LXR activation)
• Development: altered myelination
• Development: severe myelin sheath
disorganization
Makoukji et al., 2011; Hichor et al., 2016
TLR SIGNALING
TLRs • TLR2, TLR4, MyD88 KO mice • Injury: impaired expression of inflammatory
modulators, macrophage recruitment and
activation, axonal regeneration and functional
recovery
Boivin et al., 2007
GPCR SIGNALING
Gpr126 • PLPCreERT2/Gpr126fl/fl • Injury: defects in remyelination, macrophage
recruitment and axon regeneration
Mogha et al., 2016b
(Continued)
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TABLE 1 | Continued
Molecular
component
In vivo model(s) Phenotype(s) Reference(s)
Nrg1/ErbB2-B3
Nrg1 • Animals treated with Nrg1 isoforms
• Inactivation in axons:
SLICK-ACre; CAGCreERT2/Nrg1fl/fl
• Inactivation in SCs: DhhCre/Nrg1fl/fl
• Injury: improved nerve regeneration and functional
recovery
• Injury: slower axon regeneration, target
reinnervation, remyelination, functional recovery
• Injury: impaired remyelination
Chen et al., 1998; Joung et al., 2010;
Fricker et al., 2011, 2013; Yildiz et al.,
2011; Stassart et al., 2013
BACE1 • BACE1 KO mouse • Injury: impaired remyelination but enhanced axon
regeneration
Hu et al., 2008; Farah et al., 2011
TACE • HB9Cre/TACEfl/fl • Development: hypermyelination La Marca et al., 2011
ErbB2 • Mice treated with ErbB2 inhibitor
• Plp1CreERT2ErbB2fl/fl
• Injury: decreased demyelination
• Injury: no effect on SC proliferation and survival
Guertin et al., 2005; Atanasoski et al.,
2006
TABLE 2 | Summary of the regulators and their roles in SCs.
Negative regulation of myelination
during development
Positive regulation of myelination
during development
c-Jun, Notch, Sox2, Pax-3, Id2, Egr-1,
Egr-3, Cdkn1c, Hes5, Dock7, Cthrc1,
p38MAPK, BMP7, SSeCKS, Cadm3,
Dlg1, PTEN, DDIT4, AMPK, LXR?
Zeb2, NF-κB?, PI3K/Akt/mTOR,
LXR?, Wnt, Gpr126, Gpr44, LPA1,
Nrg1/ErbB2/3
Transdifferentiation after injury Remyelination after injury
c-Jun, Notch, NF-κB?, Sox2, Ras/Raf/Erk,
Rac/JNK, p38 MAPK, Sam68, Dixdc1,
TLRs, Gpr126, Nrg1/ErbB2/3?
Zeb2, NF-κB?, Nrg1/ErbB2/3
called STK11) is inactivated in SCs and in which axons are
damaged without overt demyelination (Beirowski et al., 2014).
This suggests that moderated c-Jun up-regulation is compatible
with myelination, does not necessarily provoke demyelination
and that it is sufficient to activate the transcription of injury-
related genes (Jessen and Mirsky, 2016). In this context, it is
likely that the role of c-Jun in those diseases is to promote
neuroprotection and repair. However, if c-Jun is activated in
an uncontrolled and exacerbated manner, c-Jun could also
be detrimental. For example, the increase of c-Jun expression
in some human schwannomas may directly or indirectly be
associated with the abnormal proliferation and the absence of
myelin markers (Shivane et al., 2013).
Notch Signaling
Neurogenic locus notch homolog protein (Notch) is a
transmembrane receptor protein that, upon ligand binding,
is cleaved and generates an intracellular domain (NICD),
which acts as a transcriptional regulator. Notch controls SC
proliferation and promotes the generation of immature SCs from
Schwann cell precursors (SCPs) in vivo but also acts as a negative
regulator of myelination. It is down-regulated as myelination
proceeds and its inactivation or over-activation leads to
premature or delayed myelin formation, respectively. Moreover,
the inhibition of Notch signaling in adult mice decelerates myelin
breakdown following a nerve lesion (Woodhoo et al., 2009). The
addition of recombinant jagged1, an activator of Notch, in rat
nerves after injury improves nerve regeneration and functional
recovery (Wang et al., 2015). This indicates that stimulation of
Notch signaling in SCs could represent an interesting therapeutic
strategy to efficiently promote nerve repair. However, aberrant
activation of Notch signaling in SCs may also participate to the
development of malignant peripheral nerve sheath tumors (Li
et al., 2004).
The Transcriptional Repressor Zeb2
More recently, the function of a transcriptional repressor,
Zeb2, has been investigated in SC myelination and nerve
repair by two different teams (Quintes et al., 2016; Wu L.
M. N. et al., 2016). They both showed that mice lacking
Zeb2 in SCs develop a severe peripheral neuropathy, caused
by a failure of SC maturation. Zeb2 transcriptional repression
of negative regulators of myelination such as Notch and
SRY-related HMG-box gene 2 (Sox2) is necessary for SC
lineage progression. Although Zeb2 seems dispensable for the
establishment of the repair SCs following nerve injury, its
absence disrupts nerve regeneration and remyelination (Quintes
et al., 2016). Mechanistically, Zeb2 controls SC differentiation
and remyelination by recruiting histone deacetylases 1 and 2
(HDAC1/2) and NuRD complexes and by inhibiting a Notch–
Hey2 signaling axis (Wu L. M. N. et al., 2016).
NF-κB
The nuclear factor κB (NF-κB) transcription factor regulates a lot
of physiological processes and mediates the physiopathological
inflammatory response in many diseases. Several studies suggest
that NF-κB activation is essential for the differentiation and
myelination of SCs in vitro (Nickols et al., 2003; Yoon et al., 2008;
Limpert and Carter, 2010). Furthermore, it has been shown that
the deacetylation of NF-κBmediated byHDAC 1/2 is necessary to
control myelination in the PNS (Chen et al., 2011). Paradoxically,
by using transgenic mice in which NF-κB activation is inhibited
in SCs, Morton and colleagues demonstrated that NF-κB is
dispensable for developmental myelination in vivo (Morton
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FIGURE 2 | Molecular signaling pathways involved in SC plasticity, negative regulation of myelination and nerve repair. The injury-induced reprogramming
of SCs in regeneration-promoting cells involves a down-regulation of pro-myelinating genes including Krox-20, Oct-6, Sox10, MPZ, or MBP as well as an
up-regulation of markers characteristic of immature, de-differentiated SCs such as c-Jun and p75NTR but also specific repair-supportive proteins like BDNF or GDNF.
The signaling pathways or molecular components activating (c-Jun, Notch, MAPKs, TLRs, Gpr126, NF-κB) or inhibiting (PI3K/Akt/mTOR) this reprogramming are
represented. Some negative regulators of myelination during development (TACE1, LXRs, Dusp15, PTEN, Dlg1, DDIT4, Dock7, Zeb2) and possibly playing a role after
injury are also shown.
et al., 2013). However, they showed that the inhibition of NF-
κB signaling in SCs following sciatic nerve crush transiently
delays axonal regeneration and remyelination (Morton et al.,
2012). This highlights again the differences between immature
SCs during development and transdifferentiated repair-SCs.
Importantly, NF-κB activity is robustly enhanced after peripheral
nerve damage and in inflammatory neuropathies (Andorfer et al.,
2001; Laura et al., 2006; Smith et al., 2009; Fu et al., 2010). The
different NF-κB-induced transcriptional targets responsible for
SC beneficial effects after nerve injury still have to be determined.
Of note, the placental growth factor (PlGF) which is up-regulated
by NF-κB in SCs following injury, is critical for SC proliferation,
myelin sheath degradation, macrophage invasion and axonal
regeneration (Chaballe et al., 2011). Targeting NF-κB or its
downstream targets in SCs may offer new therapeutic strategies
for PNS regeneration. Nevertheless, it is essential to keep in mind
that aberrant activation of NF-κB may also lead to schwannoma
(Ammoun et al., 2014; Dilwali et al., 2015).
Sox-2, Pax-3, Id2, Egr-1, Egr-3
Other factors that regulate gene transcription have been studied
in SC dedifferentiation. These are most of the time negative
regulators of myelination that functionally counteract positive
regulators of myelination including Krox-20 or Oct-6 and are
likely to have major roles after nerve damage (Jessen and Mirsky,
2008). For instance, the transcription regulators Sox-2, paired
box protein 3 (Pax-3), DNA-binding protein inhibitor 2 (Id2) and
early growth response proteins 1 and 3 (Egr-1 and Egr-3) could
represent good candidates for regulating SC dedifferentiation in
damaged nerves. As for c-Jun or Notch, they are inactive or
expressed at low levels in myelinating cells and re-expressed at
high levels under conditions that lead to SC dedifferentiation
such as nerve injury (Kioussi et al., 1995; Nikam et al., 1995;
Stewart et al., 1997; Le et al., 2005; Parkinson et al., 2008;
Doddrell et al., 2012). In vitro, Sox2, Pax3, and Id2 decrease or
increase myelin gene expression when overexpressed or depleted,
respectively (Kioussi et al., 1995; Mager et al., 2008; Parkinson
et al., 2008; Doddrell et al., 2012). Egr1 and Egr3 are both
necessary to up-regulate p75NTR in SC primary cultures, known
to be re-expressed in SCs following a nerve injury (Nikam et al.,
1995; Topilko et al., 1997; Gao et al., 2007). It remains to be
unraveled by in vivo evidence whether those different factors are
required for SC response after nerve injury.
Besides its likely role in SC plasticity, it has been shown that
Sox-2 is necessary in SCs for the formation of a nerve bridge after
a complete transection. This process is mediated by an ephrin-
B/EphB2 signaling between fibroblasts and SCs that initiates cell
sorting, followed by directional collective cell migration of SCs
out of the nerve stumps to guide axons across the injury wound
(Parrinello et al., 2010).
MAPK Signaling
A growing number of studies provide evidence on the functions
of mitogen activated protein kinase (MAPK) family proteins
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in the regulation of SC plasticity. Extracellular signal regulated
kinase (Erk), c-jun N-terminal kinase (JNK) and p38 MAP
kinase are rapidly and highly activated in the SCs of the distal
stump following a nerve lesion and play specific, overlapping or
complementary roles in the SC response after injury (Sheu et al.,
2000; Harrisingh et al., 2004; Zrouri et al., 2004; Agthong et al.,
2006; Parkinson et al., 2008; Lee et al., 2014; Ronchi et al., 2016).
Ras/Raf/Erk
Harrisingh and coworkers were the first ones to demonstrate
the role of the Ras/Raf/Erk signaling in SC dedifferentiation
(Harrisingh et al., 2004). They showed that the ectopic
activation of Raf, an upstream activator of Erk, suppresses
the differentiation of primary SCs induced by cyclic
adenosine monophosphate (cAMP). Raf activation in cultured
differentiated SCs also drives their dedifferentiation. Importantly,
they demonstrated that sustained activation of the Ras/Raf/Erk
pathway in myelinated dorsal root ganglion (DRG) neuron-SC
co-cultures induces demyelination even in the presence of
normal axon signaling. Consistent with this idea, another paper
reported that the dual specificity phosphatase 15 (Dusp15)
is necessary for full activation of Erk and that its activation
represses the expression of several myelin genes including MBP
(Rodríguez-Molina et al., 2017). While high and sustained
activation of Ras/Raf/Erk signaling seems essential for SC
plasticity, Ras over-activation might also be deleterious and lead
to the development of SC-derived tumors in neurofibromatosis
type 1 patients (Harrisingh et al., 2004). A strong activation of
Erk has actually been reported in human primary schwannoma
cells (Ammoun et al., 2008).
More recently, the strategy of Raf high activation has been
used in vivo to determine whether this signaling was central
in controlling SC plasticity (Napoli et al., 2012). Napoli et al.
demonstrated that a tamoxifen-inducible Raf transgene in SCs
is sufficient to induce the down-regulation of myelin proteins
and the expression of dedifferentiation markers such as p75NTR,
even in the absence of axonal damage. The duration of Raf
activation, controlled by the period of tamoxifen treatment,
determines the time frame of SC demyelination and proliferation.
A prolonged tamoxifen treatment and activation of Raf in SCs
also induces an inflammatory response, which includes the
breakdown of the blood-nerve barrier and the infiltration of
macrophages, which promote nerve regeneration.
Although the repression of Erk signaling with specific
inhibitors blocks SC mitosis, cytokine expression and
demyelination, it only prevents partially the induction of
p75NTR or GDNF and the shutdown of myelin gene expression
(Napoli et al., 2012; Shin et al., 2013). Thus, even if the sustained
and pronounced activation of the Ras/Raf/Erk pathway is
fundamental in regulating SC plasticity, this supports the idea
that several independent mechanisms control multiple aspects
of SC plasticity. Moreover, different studies showed that Erk
activation is actually pro-myelinating and that its inhibition
blocks SC differentiation and myelination in vivo (Grossmann
et al., 2009; He et al., 2010; Newbern et al., 2011). Therefore, Erk
signaling is necessary both for the differentiation of SCPs and
for the dedifferentiation of adult SCs following a nerve injury.
The reconciling explanation could be that distinct levels of Erk
activity would define the state of SC differentiation. Low or basal
activity would be required for SC differentiation while high Erk
levels would drive dedifferentiation and proliferation (Napoli
et al., 2012; Newbern and Snider, 2012).
Finally, the role of c-Jun as a downstream target of Erk
signaling is an attractive idea but it is actually quite controversial
and further in vivo studies are necessary to better understand
the signaling mechanisms downstream of Erk in SC plasticity.
Indeed, Syed et al. showed that Erk inhibition abolishes both
the demyelination and the expression of c-Jun induced by
Neuregulin 1 (Nrg1) treatment in SC-DRG neuron co-cultures
(Syed et al., 2010). Additionally, the Lloyd group indicated that
c-Jun is strongly up-regulated after Raf over-activation in SCs
in vivo (Napoli et al., 2012). However, others reported that
the induction of c-Jun and SC dedifferentiation triggered by
cAMP removal in vitro depends on JNK rather than on Erk
activity (Monje et al., 2010; Shin et al., 2013). Actually, other
data revealed that Rac/JNK and Raf/Erk might be responsible
for different complementary functions in SC plasticity. For
example, microarray experiments showed that the expression
of regeneration-associated genes, including p75NTR or GDNF
is dependent on JNK but not on Erk signaling. In addition,
it has been demonstrated that most Erk-dependent genes in
dedifferentiated SCs do not require Rac activity (Shin et al., 2013).
Rac/JNK
JNK is another MAPK that plays important functions in SCs. It
has been demonstrated that c-Jun activation by JNK is essential
for SC migration and proliferation in vitro (Parkinson et al.,
2001, 2004; Yamauchi et al., 2003). Parkinson and colleagues
showed that overexpressing the MAPK kinase 7 (MKK7), a
protein upstream of JNK, in SC primary cultures, inhibits
myelin gene expression by elevating c-Jun, suggesting a role
for JNK signaling in SC plasticity (Parkinson et al., 2008). This
was confirmed by Monje et al. who revealed that a reduction
of cAMP in vitro is sufficient to induce SC dedifferentiation
through a JNK-dependent mechanism (Monje et al., 2010).
More recently, it has also been demonstrated that the active
Rac1 GTPase (Rac), an upstream regulator of MKK7 and JNK,
inhibits SC differentiation. In SC cultures, Rac up-regulates
c-Jun and down-regulates Krox-20 through the MKK7/JNK
pathway, but not through the Raf/Erk pathway. Furthermore,
MKK7 activation and the induction of c-Jun observed in sciatic
nerves after axotomy were blocked by Rac inhibition (Shin
et al., 2013). In addition, Rac activation has been observed in
the distal stump of injured nerves, and specific Rac inhibition
with a dominant negative Rac1 and Rac1-RNAi decelerates
myelin sheath fragmentation. Rac would actually promotemyelin
sheath fragmentation by controlling actin polymerization in the
Schmidt-Lantermann incisures of SCs (Jung et al., 2011).
The cyclin-dependent kinase inhibitor 1 (Cdkn1c), also called
p57Kip2, is a protein first known to block G1/S transition during
cell cycle that also regulates actin filament dynamics through the
translocation of LIM domain kinase 1 (LIMK1), a downstream
effector of Rac/Cdc42/Rho (Yokoo et al., 2003; Heinen et al.,
2013). Knocking down Cdkn1c in cultured SCs leads to cell cycle
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exit, morphological changes and up-regulation of myelin genes.
In SC-DRG neuron co-cultures, Cdkn1c depletion accelerates
myelination. A global gene expression analysis also revealed
a shift of the transcriptional expression program toward the
pattern of differentiating SCs, strongly suggesting a role for
Cdkn1c as an important negative regulator of myelination
(Heinen et al., 2008). The same team also showed that Cdkn1c
is a direct target of the enhancer of zeste homolog 2 (EZH2) and
identify Hes5 as a new transcriptional repressor of myelin genes
(Heinen et al., 2012). Indeed, EZH2 binds Cdkn1c promoter
and its suppression results in a decrease of histone H3K27
trimethylation, an induction of Cdkn1c expression and a down-
regulation of myelin genes in cultured primary SCs.
Yamauchi and co-workers reported that the atypical guanine-
nucleotide exchange factor dedicator of cytokinesis protein 7
(Dock7), activates Rac/Cdc42/JNK signaling in SCs to positively
regulate migration and negatively regulate differentiation and
myelination (Yamauchi et al., 2008, 2011). Indeed, knocking
down Dock7 in primary SCs results in an increase of cAMP-
mediated differentiation and in a shorter duration of activation
of Rac/Cdc42 and JNK while silencing Dock7 in mice increases
myelin thickness.
Finally, collagen triple helix repeat containing 1 (Cthrc1) is
another protein that has been linked to Rac activation in SCs.
Apra and colleagues investigated Cthrc1 function in SCs both
in vitro and in vivo (Apra et al., 2012). They showed that its
silencing inhibits SC proliferation and promotes their migration
and myelination in vitro. By using a transgenic mouse line, they
demonstrated that the overexpression of Cthrc1 in SCs leads
to a delayed myelination with SCs maintaining a proliferative
state. More recently, Zhou et al identified miR-9 as an important
negative regulator of SC migration targeting Cthrc1 after nerve
injury (Zhou et al., 2014). The up-regulation of miR-9 decreases
SC migration in culture and following nerve injury. miR-9
has also been shown to directly target Cthrc1, which in turn
inactivates downstream Rac. Finally, miR-9 is down-regulated at
a speed comparable to the rate of SC migration during nerve
regeneration, suggesting that miR-9 down-regulation could be
linked to the phenotypic modulation of SCs after nerve injury.
All these data confirm that Rac/JNK signaling is essential for
SC plasticity, proliferation and migration following nerve injury.
However, stimulating this pathway for nerve repair therapy must
be cautioned as its upregulation has also been observed in
primary human schwannoma cells (Kaempchen et al., 2003).
p38 MAPK
Yang and co-workers provided the most relevant data that
suggest a role for p38 MAPK in SC plasticity and their response
to injury (Yang et al., 2012). They reported that inhibition
of p38 MAPK activity in mice blocks SC demyelination and
dedifferentiation following nerve injury, despite ongoing axon
degeneration. In myelinating co-cultures, they also showed that
p38 MAPK mediates myelin breakdown induced by Nrg1.
Finally, while the ectopic activation of p38 MAPK is sufficient
to provoke myelin breakdown and c-Jun induction, its inhibition
in SC-DRG neuron co-cultures promotes myelination. Roberts
and collaborators recently investigated the in vivo function
of the major p38 isoform in mouse conditional knockouts.
In agreement with previous findings, the lack of p38alpha in
SCS accelerates myelination during development, delays myelin
clearance and slightly increases remyelination following injury.
However, axonal regeneration and functional repair were not
affected in the absence of p38alpha (Roberts et al., 2016).
A recent study on bone morphogenetic protein 7 (BMP7)
in SCs revealed a role for this protein as a negative regulator
of myelination through the activation of p38 MAPK signaling
(Liu et al., 2016b). Liu and collaborators showed that BMP7
expression is inversely correlated with myelin gene expression
during normal peripheral myelination. In addition, BMP7
treatment decreases cAMP-induced myelin gene expression and
up-regulates c-Jun in primary SC cultures. By using p38 MAPK
inhibitor, gene silencing and rescue experiments, they reported
that p38MAPK is responsible for BMP7-mediated suppression of
myelin gene expression. Finally, when injected in newborn rats,
BMP7 retards peripheral myelination.
PI3K/Akt/mTOR Signaling
Phosphatidylinositol 3-kinase (PI3K) signaling has been
implicated in the regulation of proliferation, survival and
differentiation of different cell types (Rameh and Cantley,
1999). The pathway is strongly activated in primary cultured
SCs following treatment with soluble Nrg1 or contact with
neurite membranes. Moreover, PI3K signaling is required
for SC proliferation and survival in vitro (Maurel and Salzer,
2000; Li et al., 2001). Its inhibition affects the initiation of
myelination but is not necessary for myelin maintenance in
SC-neuron co-cultures (Maurel and Salzer, 2000). In addition,
the selective activation of Akt in SCs by gene transfer results
in an increased myelination in SC-DRG neuron co-cultures
and allogenic nerve graft experiments. This last paper also
demonstrated opposing functions for PI3K/Akt and Erk
pathways in controlling SC myelination (Ogata et al., 2004). The
imbalanced activation of the PI3K/Akt and Erk pathways has
also been revealed in transgenic rodent models of CMT1A in
which SCs develop persistent differentiation defects during early
postnatal development (Fledrich et al., 2014). The transgenic
expression of constitutively active Akt in SCs, however does not
seem to disrupt PNS myelination in vivo (Flores et al., 2008).
Studies investigating the role of specific proteins indirectly
indicated a role for PI3K/Akt signaling in the regulation of SC
proliferation and differentiation after nerve injury. For example,
Src-associated in mitosis of 68 kD (Sam68) has been suggested to
promote SC proliferation by enhancing the PI3K/Akt pathway
and to act on regeneration following sciatic nerve crush (Wu
et al., 2016b). DIX domain containing-1 (Dixdc1), which is
also linked to PI3K/Akt activation, promotes SC proliferation
after sciatic nerve crush. Dixdc1 is up-regulated following nerve
damage and its depletion leads to reduced PI3K/Akt activation
and SC proliferation (Wu et al., 2016a). Consistently, 17β-
estradiol has been shown to promote SC proliferation and early
remyelination in the bridge after nerve transection through Akt
activation (Chen et al., 2016a). Src-suppressed protein kinase
C substrate (SSeCKS) has been indicated as a suppressor of
SC differentiation and myelination by inhibiting Akt activation.
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SSeCKS is effectively down-regulated during SC differentiation
and its depletion promotes Akt phosphorylation andmyelin gene
expression in cAMP-treated primary cultures or myelination
when co-cultured with DRG neurons (Ji et al., 2010). SSeCKS
is also essential for SC adhesion, spreading and migration (Yan
et al., 2009). In addition, Chen and collaborators showed that cell
adhesion molecule 3 (Cadm3) might act as a negative modulator
of PNS myelination. Cadm3 interferes with PI3K/Akt activation
and inhibits Schwann cell myelination in vitro (Chen M. S. et al.,
2016).
The mammalian disks large homolog 1 (Dlg1) inhibits
PI3K/Akt signaling via its interaction with the phosphatase
and tensin homolog deleted on chromosome 10 (PTEN).
This mechanism is necessary to transiently inhibit the axonal
stimulation of myelination and to limit myelin sheath thickness.
Myelin outfoldings and overmyelination followed later by
pathologic demyelination are actually observed after Dlg1
silencing via RNA interference in mouse sciatic nerves (Cotter
et al., 2010). Dlg1/PTEN functions and consequently Akt/mTOR
signaling are also disturbed in different mouse models of
demyelinating neuropathies and peripheral nerve sheath tumors
(Bolino et al., 2004; Cotter et al., 2010; Goebbels et al., 2010,
2012; Keng et al., 2012). More specifically, Goebbels et al showed
that mice lacking PTEN develop a tomaculous neuropathy
characterized by focal hypermyelination and myelin outfoldings.
Moreover, treating thesemice with rapamycin, amTOR inhibitor,
significantly ameliorates the pathology (Goebbels et al., 2010,
2012). Another study on PTEN signaling showed that the
hypermyelination observed in mice lacking Dlg1 is actually
transitory. This study also identified DNA damage-inducible
transcript 4 protein (DDIT4) as a sustained negative regulator
of myelination. High DDIT4 expression in SCs precedes the
peak of Dlg1 and Akt activity in peripheral nerves. Loss of
DDIT4 expression both in vitro and in vivo results in sustained
hypermyelination and enhanced PI3K/Akt/mTOR activation
(Noseda et al., 2013). Therefore, it is likely that PI3K/Akt
signaling has to be precisely regulated and balanced to induce SC
differentiation or dedifferentiation.
mTOR is a signaling pathway that integrates a lot of signals
(growth factors, nutrients, energy and oxygen) necessary for
growth and proliferation (Norrmén and Suter, 2013). Sherman
and collaborators demonstrated that the inactivation of mTOR
in SCs provokes an arrest of myelination after axonal sorting
and reduces axon growth (Sherman et al., 2012). More recently,
it has been reported that the conditional ablation of raptor,
an essential component of the mTORC1 complex, in SCs leads
to hypomyelination and abnormal lipid biosynthesis (Norrmén
et al., 2014). The pathways that converge to mTOR are numerous
and include Nrg1/ErbB, PI3K/Akt, MAPKS or AMP-activated
kinase (AMPK) signaling (Norrmén and Suter, 2013). AMPK
is a heterotrimeric serine/threonine protein kinase acting as an
inhibitor of mTOR and described as a crucial energy sensor
important to maintain energy homeostasis (Hardie et al., 2012).
Recently, Liu and colleagues revealed that AMPK is a critical
negative regulator of SC myelination in the PNS (Liu et al.,
2016a). They first showed that AMPK is gradually decreased as
myelination proceeds. The high activation of AMPK decreases
myelin gene expression and stimulates c-Jun expression in
SCs whereas its inhibition or depletion induces myelin gene
expression. The injection of an inhibitor of AMPK in newborn
rats downregulates c-Jun expression, enhances lipid and protein
synthesis and increases myelin gene expression and myelin
sheath thickness.
Wnt Signaling and LXR
Wnt/β-catenin pathway has been demonstrated to be crucial for
PNS development. Cell cultures and genetic experiments revealed
that Wnt signaling is required for SC lineage progression,
proliferation and myelination (Hari et al., 2002; Lee et al.,
2004; Gess et al., 2008; Grigoryan et al., 2013). Recently, it
has been proposed that interplay between Wnt pathway and
liver X receptors (LXR) induces the fine-tuning of myelin
gene expression (Makoukji et al., 2011). Oxysterols acting as
ligands for LXR, are natural compounds that originate from
the enzymatic oxidation of cholesterol. They are involved in
cholesterol homeostasis and in the progression of different
neurodegenerative disorders (Lütjohann et al., 2000; Russell,
2000; Leoni et al., 2002). Makoukji and co-workers provided
evidence for the implication of LXR and oxysterols in the
negative regulation of myelin gene expression (Makoukji et al.,
2011). They showed that oxysterols are expressed in a SC
line and in sciatic nerves and that they repress the gene
expression of MPZ and PMP22 by a mechanism involving LXR
α and β and the inhibition of the Wnt/β-catenin-dependent
pathway. Unexpectedly, although myelin gene transcripts are
up-regulated in mice lacking LXR α and β, presumably due
to increased β-catenin activity, myelin protein expression is
decreased andmyelin sheath thickness is reduced. They conclude
that this hypomyelination in the knockout animals may be
the consequence of an altered cholesterol homeostasis and
an inefficient myelin protein trafficking from the endoplasmic
reticulum.
Recently, paraquat, a redox-active herbicide, has been shown
to elicit an oxidative stress in the normal sciatic nerves of adult
mice and a dramatic disorganization of myelin sheaths, causing
severe locomotor and sensory deficits through a stimulation of
the LXR pathway leading to reduced Wnt signaling (Hichor
et al., 2016). Indeed, the authors provided evidence that paraquat
alters myelin gene expression by activating LXR signaling and by
preventing β-catenin recruitment on the myelin gene promoter.
They also indicated that treating paraquat-exposed mice with
lithium, a Wnt/β-catenin modulator acting as a GSK3 inhibitor,
prevents the deleterious defects of paraquat on sciatic nerves.
The effect of lithium chloride has also been studied after nerve
injury. It accelerates axon and myelin debris clearance and
remyelination by inhibiting GSK3 and increasing β-catenin levels
(Chen et al., 2016b).
Toll-like Receptor Signaling
The Toll-like receptors (TLRs) are a class of proteins that play
a key role in initiating the immune and inflammatory response.
After nerve injury, damage-associated molecular patterns and
ligands released from or expressed by activated or necrotic
damaged cells result in the activation of TLRs in different
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cell types including SCs (Thakur et al., 2017). TLR3, TLR4,
and TLR7 are constitutively expressed by SCs and TLR1 is
upregulated following nerve injury, strongly suggesting a role
for TLR signaling in SC-driven nerve repair (Goethals et al.,
2010). In vitro, the addition of necrotic neurons to SCs
activates their inflammatory response through TLR signaling.
It increases their gene expression of inflammatory mediators
such as tumor necrosis factor-alpha (TNF-α) or monocyte
chemoattractant protein-1 (MCP-1) but this effect is reduced
in SCs from mice lacking TLR3 (Lee et al., 2006). Boivin and
collaborators provided in vivo evidence that TLR signaling is
involved inWD and nerve regeneration following a nerve injury,
possibly through NF-κB activation (Boivin et al., 2007). The
early expression of inflammatory modulators such as MCP-1,
macrophage recruitment and activation, axonal regeneration and
functional recovery are impaired in the mice deficient in TLR
signaling. The results are indeed similar in mice lacking TLR2,
TLR4 or their adaptor, myeloid differentiation primary response
gene 88 (MyD88) known to activate NF-κB. Interestingly, a single
injection of TLR2 and TLR4 ligands at the site of the lesion
speeds up myelin clearance and functional recovery. Besides
its likely role in SC response to nerve injury, TLR signaling
has also been linked to the development of neuropathic pain,
making TLRs promising therapeutic targets (Thakur et al.,
2017).
GPCR Signaling
To date, three different G protein-coupled receptors (GPCRs)
have been demonstrated to be implicated in SC differentiation.
These are Gpr126, Gpr44, and lysophosphatidic acid receptor
1 (LPA1) (Mogha et al., 2016a). Monk and colleagues were
the first ones to show that a GPCR, Gpr126, is crucial for
the initiation of SC myelination (Monk et al., 2009). The
analysis of mice lacking LPA1 then revealed that this receptor
is required for SC migration, axonal sorting and proper
myelination (Anliker et al., 2013). Finally, Trimarco et al.
provided in vitro and in vivo evidence for the involvement of
Gpr44 and its ligand the prostaglandin D2 in PNS myelination
(Trimarco et al., 2014). Very recently, Mogha and collaborators
investigated the potentiel functions of Gpr126 in peripheral
nerve injury and repair as its expression is maintained in adult
SCs (Mogha et al., 2016b). By using an inducible conditional
Gpr126 knockout model, they observed defects in remyelination,
macrophage recruitment and axon regeneration following a
nerve crush. Since approximately 30% of all approved drugs
target GPCRs, Gpr126 may represent an attractive potential
target to stimulate repair in myelinating disease or after nerve
damage.
Nrg1/ErbB2/3 Signaling
Currently, the signals from damaged nerves that induce the
reprogramming of SCs are not identified. Some argued that
these can be linked to the Nrg1/ErbB pathway, one of the best
described interdependent relationship between axons and SCs.
Neuregulins form a large family of epidermal growth factor-like
proteins that signal through the ErbB tyrosine kinase receptors
(Falls, 2003). The Nrg1/ErbB signaling is first of all known for
its critical functions in SC development (for review, Newbern
and Birchmeier, 2010; Grigoryan and Birchmeier, 2015; Willem,
2016). Indeed, numerous genetic models have been generated
to unravel fundamental functions of the Nrg1/ErbB signaling
axis. Differential expression of Nrg1 isoforms, their proteolytic
processing or ErbB receptor localization and trafficking are
important parameters that control the Nrg1/ErbB pathway and
its underlying functions. Depending on the developmental stage,
the pathway significantly regulates SC survival, proliferation,
migration, differentiation and myelination (Syroid et al., 1996;
Morris et al., 1999; Leimeroth et al., 2002; Taveggia et al., 2005;
Chen et al., 2006; Freidin et al., 2009; Newbern and Birchmeier,
2010). This functional diversity is presumably accomplished
through the interaction of Nrg1/ErbB signaling with other
pathways. For instance, Notch signaling, which is necessary for
SCP proliferation and survival, increases the expression of ErbB2
in SCPs and their sensitivity to Nrg1 (Woodhoo et al., 2009).
The tyrosine phosphatase Shp2 is another essential component
of the Nrg-1/ErbB pathway that promotes SC proliferation and
migration (Grossmann et al., 2009). Later in SC development,
critical interactions between Nrg1/ErbB and cAMP or NF-κB
signaling are necessary for SC differentiation and myelination
(Limpert and Carter, 2010; Arthur-Farraj et al., 2011). Although
the importance of Nrg1/ErbB signaling in SC development is well
established, its role in adult SC plasticity is more controversial. In
adulthood, the pathway seems dispensable for themaintenance of
the myelin sheaths, as the absence of Nrg1 in peripheral axons or
of ErbB2 in SCs has no effect on axon or myelin sheath integrity
(Atanasoski et al., 2006; Fricker et al., 2011, 2013). However,
increasing evidence indicates that Nrg1 is necessary for the SC
response to nerve injury.
The fact that the Nrg1/ErbB system is selectively and highly
regulated during peripheral nerve degeneration and regeneration
represents a strong argument in favor of a role for this signaling
pathway in SC plasticity (Carroll et al., 1997; Kwon et al.,
1997; Ronchi et al., 2016). Recently, a study using a rat surgical
model of delayed nerve repair showed that Nrg1 and some SC
markers are highly down-regulated after chronic degeneration.
Since long-term denervated Schwann cells are known to be
partly responsible for delayed nerve repair, it suggests that Nrg1
plays an important function in SC activity after denervation
(Ronchi et al., 2017). Guertin and colleagues showed that ErbB2 is
activated in myelinating SCs after sciatic nerve axotomy and that
its transient activation is sufficient to initiate SC demyelination
in compartmentalized cell culture chambers. In addition, the
treatment of rats with an ErbB2 inhibitor results in a reduction
of demyelination after nerve transection (Guertin et al., 2005).
Consistently, Syed et al demonstrated that a robust activation
of ErbB2/3 via high concentration of soluble Nrg1 induces SC
dedifferentiation and demyelination as well as increased c-Jun
expression in primary cultures (Syed et al., 2010). Furthermore, in
vitro experiments recapitulating nerve injuries provide evidence
that Nrg1 treatment shows beneficial effects on SC migration
and proliferation (Mahanthappa et al., 1996; Li et al., 1998).
Finally, Lee and collaborators showed that Nrg1 on motor axons
controls the terminal SC-mediated synapse elimination at the
neuromuscular junctions (NMJs) during development. They also
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revealed that NMJs of adult transgenic mice overexpressing Nrg1
in motor axons exhibited continued remodeling, identifying
Nrg1 as a molecular determinant for SC-driven neuromuscular
synaptic plasticity (Lee et al., 2016).
Nrg1/ErbB signaling has also been linked to different
pathways mentioned earlier for regulating SC plasticity. For
example, Nrg1 has been proposed as the signal driving high Erk
activation after injury (Napoli et al., 2012). High concentrations
of Nrg1 indeed highly activates Erk signaling and induces
SC dedifferentiation and demyelination (Syed et al., 2010;
Newbern and Snider, 2012). In agreement with this, Tapinos and
collaborators also showed that direct binding of Mycobacterium
leprae onto ErbB2 receptors on SCs activates Erk signaling
and promotes demyelination (Tapinos et al., 2006). Another
possibility is that Nrg1 could trigger Rac/JNK activation. Indeed,
the inhibition of ErbB2 signaling has been shown to prevent
MKK7 activation, c-jun expression, and Rac-dependent gene
transcription in cultures of sciatic nerve explants (Shin et al.,
2013). ErbB2 also directly binds and activates the negative
regulator of myelination, Dock7, upstream of Rac/JNK while
the depletion of Dock7 attenuates Nrg1 effects in primary SC
cultures (Yamauchi et al., 2008, 2011). Although these data
suggest a role for Nrg1/ErbB signaling in SC dedifferentiation,
in vivo studies revealed contradictory results. Atanasoski et al.
showed that lack of ErbB2 in adult SCs does not affect their
proliferation and survival after nerve injury, despite reduced
levels of phosphorylated MAPK (Atanasoski et al., 2006). In
addition, the absence of the axonal Nrg1 following a nerve
crush does not disturb SC proliferation associated with nerve
degeneration or the clearance of myelin debris by macrophages.
Therefore, adult SCs would not require major Nrg1/ErbB
signaling for their proliferation and survival after nerve damage,
in contrast to what is observed in vitro and during development.
While the implication of Nrg1 signaling in the
dedifferentiation of SCs is unclear, its involvement in
myelination but also in remyelination after nerve injury is
now well established. The transmembrane axonal isoforms
Nrg1 type III signals in a juxtacrine manner through ErbB2/3
receptors on SCs and determines their myelin thickness, both
during development and following a nerve lesion (Michailov
et al., 2004; Taveggia et al., 2005; Fricker et al., 2011, 2013). The
axonal Nrg1 is rate limiting but not essential for remyelination
since compensations are observed at later stages (Fricker et al.,
2013). All the same, myelin sheaths are often thinner after
injury, suggesting an insufficent simulation by axonal signals
(Schröder, 1972). Another mechanism is actually induced in
SCs to supplement these poor neuronal cues. Nerve damage
triggers the expression of soluble Nrg1 type I by SCs themselves.
This particular autocrine and paracrine signaling in SCs is
only required after nerve injury and promotes SC survival,
redifferentiation and remyelination (Fricker and Bennett, 2011;
Stassart et al., 2013).
Besides the importance of Nrg1/ErbB signaling in SC
remyelination, it also plays a key role in repair processes after
nerve injury (Fricker and Bennett, 2011). Fricker and colleagues
showed that the absence of Nrg1 in adult axons after sciatic
nerve crush results in defects of remyelination but also in
slower axon regeneration, impaired muscle reinnervation and
delayed functional recovery (Fricker et al., 2011, 2013). In a
mouse model lacking β-Site amyloid precursor protein cleaving
enzyme 1 (BACE1), a protein known to cleave and activate
Nrg1 type III, SC remyelination is impaired and nerve repair
is surprisingly accelerated (Hu et al., 2008). Indeed, knockout
mice show an accelerated clearance of axonal and myelin
debris from degenerated fibers, faster axonal regeneration and
earlier reinnervation of neuromuscular junctions, compared to
littermate controls (Farah et al., 2011). The enhanced myelin
clearance might clearly be due to the initial hypomyelination
observed in adult BACE1 KO sciatic nerves. However, how
BACE1 deletion enhances peripheral regeneration still needs to
be clarified. Another enzyme capable of cleaving the axonal Nrg1,
counteracting BACE1 and interfering with SC differentiation
is the tumor necrosis factor-α–converting enzyme (TACE,
also named ADAM17). TACE depletion in SC-DRG neuron
co-cultures increases myelination. The absence of TACE in
motoneurons in vivo results in hypermyelination. The function
of TACE is neuron autonomous since its knockdown in SCs
does not affect myelination. Mechanistically, TACE cleaves Nrg1-
III, which is no longer capable of activating PI3K signaling
and inducing myelination (La Marca et al., 2011). Therefore,
TACE can be considered as a modulator of NRG1 type III
activity and as a negative regulator of SC myelination. The role
of Nrg1 in peripheral regeneration has also been demonstrated
in different studies examining the effects of Nrg1 treatment
following nerve injury. The application of exogenous Nrg1
or strategies that elevates Nrg1 levels after nerve damage
improve myelin clearance, axon regeneration, remyelination and
functional recovery (Chen et al., 1998; Joung et al., 2010; Fricker
and Bennett, 2011; Yildiz et al., 2011). Therefore, treatment
with recombinant forms of Nrg1 may represent interesting
therapeutic avenues to improve nerve repair following injury. It
is however necessary to better understand the mechanisms by
which Nrg1 treatment improves nerve regeneration.
Finally, it is essential to remember that the inappropriate
overactivation of Nrg1/ErbB signaling pathway may be harmful
in some circumstances and lead to demyelinating neuropathies
or peripheral tumors. For instance, constitutive activation of
the Nrg1/ErbB pathway promotes the proliferation of peripheral
neuroepithelioma and neoplastic SC line (Frohnert et al., 2003;
Fallon et al., 2004). Similarly, transgenic mice over-expressing
Nrg1 in myelinating SCs develop hypertrophic neuropathies and
malignant peripheral nerve sheath tumors (Huijbregts et al.,
2003). In addition, leprosy, which is an important cause of
demyelinating neuropathy in the world, is initiated by an
excessive activation of ErbB2 byM. leprae (Tapinos et al., 2006).
PATHOPHYSIOLOGICAL IMPLICATIONS
AND THERAPEUTIC STRATEGIES
Peripheral neuropathies are responsible for significant morbidity
and decreased quality of life due to weakness, sensory loss and
neuropathic pain. The causes are multiple: peripheral nerve
traumatic injuries, inherited genetic diseases such as CMT,
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metabolic disorders including diabetes, infectious, toxic and
inflammatory disorders (Zhou and Notterpek, 2016). Peripheral
nerves have an impressive ability to regenerate compared to
the CNS. However, the clinical recovery of patients suffering
from peripheral neuropathies is often incomplete due to
slow regeneration rate, target mis-reinnervation and lack of a
long-term regeneration-supportive environment. After injury,
peripheral axons regenerate at a very slow rate of approximately
1 mm per day, depending on the lesion site. Moreover, the
regenerative capacity of the PNS decreases over time. Indeed,
SCs become unsupportive to regeneration after long periods
and they also exhibit diminished plasticity with age (Fu and
Gordon, 1995; Zochodne, 2012; Painter et al., 2014). Of note,
Joshi and coworkers recently demonstrated that SCs show an
altered expression of c-Jun and Cdkn1c and that their pro-
regenerative functions are diminished in a model of chronic
inflammatory demyelinating polyneuropathy (CIDP) (Joshi et al.,
2016). A better understanding of the signaling pathways that
drive SC reprogramming and plasticity is of great interest and
may offer new opportunities to enhance nerve repair. SCs are the
main effectors of regeneration in many peripheral diseases and
recent studies clearly positioned SCs at the hub for organizing the
environment to clear myelin debris, promote axonal regrowth,
remyelination and allow complete functional repair following
injury (Zochodne, 2012; Kim et al., 2013).
The different signaling pathways and molecular components
described in the present review represent interesting targets
to boost the endogenous regeneration potential of SCs. For
instance, the treatment with different Nrg1 isoforms or strategies
to stimulate ErbB signaling have actually been shown to
improve myelin clearance, axon regeneration, remyelination
and functional recovery after nerve injury in different studies
(Chen et al., 1998; Joung et al., 2010; Fricker and Bennett,
2011; Yildiz et al., 2011). In a CMT1A rat model, soluble
Nrg1 therapy during early postnatal life prevents abnormal
developmental demyelination and subsequent axon loss observed
in adulthood (Fledrich et al., 2014). The overexpression of
Nrg1 in mouse models of amyotrophic lateral sclerosis (ALS)
and partial muscle denervation improves functional recovery
by enhancing collateral reinnervation sprouting through both
Akt and Erk pathways (Mancuso et al., 2016). Notch activation
through the addition of a recombinant jagged1 after injury also
promotes nerve regeneration and functional recovery (Wang
et al., 2015). The inhibition of mTOR signaling with rapamycin
in mice that lack PTEN and develop a tomaculous neuropathy
significantly ameliorates the pathology (Goebbels et al., 2012).
Finally, stimulating TLR signaling at the site of the lesion
accelerates myelin clearance and functional recovery (Boivin
et al., 2007).
Additional molecules, not directly linked to pathways
analyzed in this review, have been shown to regulate SC
differentiation/dedifferentiation and improve nerve repair. For
example, Fingolimod, an agonist of the sphingosine-1-phosphate
receptor (S1PR), previously known to affect SC migration and
myelination in vitro and currently in clinical trial for the
treatment of CIDP, has been demonstrated to modulate SC
plasticity (Köhne et al., 2012; Heinen et al., 2015). Fingolimod
activates different dedifferentiation markers such as c-Jun,
increases the expression of growth factors, slows myelination and
improves axon regeneration. Therefore, Fingolimod supports the
generation of a repair promoting cellular phenotype and could
be used for the treatment of peripheral nerve damages and
diseases (Heinen et al., 2015). Its mechanism of action, however,
still remains to be elucidated. Another recent example is the
addition of TGF-β1 and forskolin directly on chronically injured
nerves that can reactivate the growth-supportive environment
through the reprogramming of chronically denervated SCs, the
re-induction of their proliferation, and the re-expression of
regeneration-associated proteins (Sulaiman and Nguyen, 2016).
Immunoglobulins (IVIG) are another therapeutic strategy widely
used to treat immune-mediated neuropathies such as CIDP.
Tzekova and colleagues demonstrated that IVIG positively
influence SC differentiation and maturation and increase their
potential to induce axonal outgrowth (Tzekova et al., 2015).
Other approaches that are based on SC regenerative properties
and improve nerve repair can also be addressed. First, exercise
and electrical stimulation have been demonstrated to promote
SC-driven peripheral nerve regeneration in both animal models
and in human patients (Gordon and English, 2016). Second,
transplantations of SCs from healthy nerves or engineered
from different tissues thanks to the emergence of the induced
pluripotent stem cell technology are another interesting method
to support nerve healing (Zhou and Notterpek, 2016). Actually,
numerous SC-based therapies also exist to promote repair in the
lesioned CNS (Matsas et al., 2008). Third, there has been major
progress in developing biomaterials that improve regeneration
by providing trophic factors or by supporting the regenerative
functions of transplanted cells in situ (Marquardt and Sakiyama-
Elbert, 2013). For example, Liu and colleagues recently showed
that Salidroside and tissue engineering using SCs and poly
lactic-co-glycolic acid promote peripheral nerve regeneration
and functional recovery after sciatic nerve transection in rats.
Salidroside increases the proliferation and regenerative function
of SCs, probably through the modulation of neurotrophic
factors (Liu et al., 2017). Fourth, gene therapy that allows to
deliver genetic material directly into somatic cells is another
option to treat neuropathies that involve gene mutations
or to improve nerve regeneration after injuries (Zhou and
Notterpek, 2016). In hereditary diseases including CMTs, loss
or gain of function mutations could be restored through
the re-expression of the absent or non-functional protein or
through the down-regulation of the mutant mRNA via RNA
interference strategy, respectively. For example, Kagiava and
coworkers recently demonstrated that the intrathecal injection
of a lentiviral vector with a myelin-specific promoter restored
the expression of a neuropathy-associated gene and rescued a
model of demyelinating peripheral neuropathy (Kagiava et al.,
2016). Also, other studies based on gene therapy in order to
improve nerve regeneration used lentiviral vectors that potentiate
the therapeutic functions of SCs transplanted in artificial nerves,
in autografts or present in damaged nerves (Hoyng et al., 2015).
Even if SCs are known to mainly support nerve repair through
an enhanced expression of neurotrophic factors that stimulate
axon regeneration and myelination, this review highlights the
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numerous additional roles and regenerative functions of SCs in
nerve injuries and in demyelinating diseases. Therefore, targeting
the molecular mechanisms that regulate SC reprogramming
by gene therapy can be highly promising to stimulate nerve
healing. In the future, the challenges will be to optimize gene
therapy in order to specifically target SCs and to create safe
and regulatable vectors to potentiate their regenerative functions
in the appropriate timings. Lipid-based nanoparticles such as
liposomes or extracellular vesicles are other valuable tools for
the delivery of small molecules or genes that can modulate
signaling pathways and promote nerve repair (Takeda and Xu,
2015). In order to selectively introduce material into SCs, Lee
and colleagues developed phospholipid-based liposomes that
can enter SCs when injected in tail vein and showed that the
nanoparticles escape the endogenous degradative mechanisms
in vitro (Lee et al., 2013). In the following years, it is expected
that the improvements in cell and tissue engineering and in
approaches that target SC capacity to promote regeneration will
lead to the development of innovative and efficient PNS repair
strategies.
The different therapeutic options that are built on or
that stimulate SC plasticity represent new avenues for nerve
regeneration but should be considered with prudence for
different reasons. First, a prolonged stimulation of SC
dedifferentiation could disrupt the remyelination of the
regenerated axons, necessary for rapid nerve conduction and
complete functional recovery. Also, the aberrant activation
of some pathways including Notch, NF-κB, Ras/Raf/Erk,
Rac/JNK, or Nrg1/ErbB can lead to abnormal cell proliferation
and the development of peripheral nerve tumors. The better
understanding of the molecular mechanisms regulating SC
plasticity is thus necessary to set up therapies that modulate both
temporally and quantitatively SC capacity to drive nerve repair
without affecting remyelination and increasing the chances of
triggering tumor development.
CONCLUSIONS
The remarkable capacity of regeneration of the PNS compared
to the CNS is mainly due to the fantastic plasticity of SCs.
The molecular components involved in the negative regulation
of myelination and in the reprogramming of SCs in response
to nerve injury provide important mechanistic insights and
new therapeutic approaches into peripheral neuropathies as
well as in peripheral nerve regeneration. However, this review
demonstrates the complexity of themolecular signaling pathways
and reveals that little is known about the interactions between
them. Moreover, the temporal and quantitative activation of
the different signals identified is of great importance but is not
completely elucidated. Future studies are thus required to better
understand the cross-talks, networks and activation patterns and
timings between the different molecular mechanisms controlling
SC plasticity.
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